Opinion
Video
Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.
Video content above is prompted by the following:
- What patient populations stand to benefit the most from recently approved bispecific therapies?
- Where are gaps or opportunities for patient populations to further benefit from bispecifics?
- What data gaps exist in understanding the optimal use of bispecific antibodies across various cancer types?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
